Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells 11,112 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the completion of the transaction, the chief technology officer directly owned 166,912 shares in the company, valued at $3,097,886.72. This trade represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Woo also recently made the following trade(s):

• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The shares were sold at an average price of $18.25, for a total value of $147,587.75.
• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total transaction of $13,951.95.

CeriBell Stock Performance

Shares of CeriBell stock remained flat at $18.57 on Friday. 217,757 shares of the stock traded hands, compared to its average volume of 301,845. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. The stock has a market cap of $698.97 million, a P/E ratio of -12.63 and a beta of 0.94. The company has a 50 day moving average of $19.39 and a 200 day moving average of $17.37. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $24.33.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The company had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. As a group, research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. Geode Capital Management LLC raised its stake in shares of CeriBell by 55.4% in the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after acquiring an additional 159,698 shares during the period. JPMorgan Chase & Co. boosted its holdings in CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its stake in shares of CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after acquiring an additional 17,177 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after buying an additional 1,256 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in shares of CeriBell in the second quarter worth $317,000.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group raised their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.